Table 1.
Results from serological, parasitological, microscopy-histology, and molecular assays, distributed according to clinical status.
| Clinical Presentation | Conventional Diagnosis (IFAT, PC, MH) | Real-Time PCR (qPCR) kDNA | |||
|---|---|---|---|---|---|
| Clinical Samples | IFAT Positive/Total (%) |
PC Positive/Total (%) |
MH Positive/Total (%) |
Positive/Total (%) | |
| VL | Peripheral blood/serum | 13/15 (86.6) | 4/15 (26.6) | 10/15 (66.6) | 13/15 (86.6) |
| Bone marrow | n.a. | 8/15 (53.3) | 13/15 (86.6) | 15/15 (100) | |
| CL | Tissue/skin biopsy | n.a. | 9/15 (60) | 10/15 (66.6) | 15/15 (100) |
| CanL | Peripheral blood/serum | 19/30 (63.3) | 5/30 (16.6) | 5/30 (16.6) | 19/30 (63.3) |
| Popliteal lymph node | n.a. | 16/30 (53.3) | 17/30 (56.6) | 30/30 (100) | |
| FeL | Peripheral blood/serum | 8/20 (40) | 0/20 (0) | 0/20 (0) | 1/20 (5) |
| Popliteal lymph node | n.a. | 1/20 (5) | 1/20 (5) | 20/20 (100) | |
IFAT, indirect immunofluorescent assay; PC, Parasite culture; MH, microscopy-histology; qPCR, quantitative PCR; VL, human visceral leishmaniasis; CL, human cutaneous leishmaniasis; CanL, canine leishmaniasis; FeL, feline leishmaniasis; n.a., not applicable.